Samsung Bioepis

E850006

Samsung Bioepis is a South Korean biopharmaceutical company specializing in the development and commercialization of biosimilar medicines.

Try in SPARQL Jump to: Statements Referenced by

Statements (48)

Predicate Object
instanceOf biopharmaceutical company
biosimilar manufacturer
businessModel commercialization of biosimilars
development of biosimilars
collaboratesWith Biogen NERFINISHED
Biogen Idec NERFINISHED
Merck & Co. NERFINISHED
Organon NERFINISHED
country South Korea
focusesOn diabetes
immunology
oncology
ophthalmology
followsRegulatoryGuidelinesOf European Medicines Agency NERFINISHED
U.S. Food and Drug Administration NERFINISHED
foundedAsJointVentureWith Biogen NERFINISHED
hasOfficialWebsite https://www.samsungbioepis.com
hasProduct Amelivu NERFINISHED
Aybintio NERFINISHED
Benepali NERFINISHED
Flixabi NERFINISHED
Hadlima NERFINISHED
Imraldi NERFINISHED
Ontruzant NERFINISHED
Renflexis NERFINISHED
hasProductType adalimumab biosimilar
bevacizumab biosimilar
etanercept biosimilar
infliximab biosimilar
insulin glargine biosimilar
trastuzumab biosimilar
hasResearchAndDevelopmentCenterIn Incheon GENERATED
headquartersLocation Incheon NERFINISHED
Songdo International Business District NERFINISHED
industry biopharmaceutical
biotechnology
pharmaceutical
languageOfName Korean
parentOrganization Samsung Biologics NERFINISHED
Samsung Group NERFINISHED
partOf Samsung Life Science business NERFINISHED
regulatoryApprovalIn Australia NERFINISHED
Canada NERFINISHED
European Union NERFINISHED
South Korea NERFINISHED
United States NERFINISHED
specializesIn biologic medicines
biosimilars

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Renflexis isManufacturedBy Samsung Bioepis